Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today

#IKT Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

www.stocktitan.net/news/IKT/inhibikase-ther...

EBA-Folgebericht: Fortschritte bei IKT-Risikoaufsicht unter DORA – weitere Harmonisierung nötig Die EBA bewertet die IKT-Risikoaufsicht im SREP: Behörden machen Fortschritte dank DORA, doch EU-weite Konvergenz bleibt eine offene Aufgabe.

Die Europäische Bankenaufsichtsbehörde (EBA) hat einen Folgebericht zu ihrem Peer-Review von 2022 über die Bewertung von IKT-Risiken im Rahmen des aufsichtlichen Überprüfungs- und Bewertungsprozesses (SREP) veröffentlicht.
www.all-about-security.de/eba-folgeber...
#eba #ikt #dora

Goienak argitaratzen duen #PUNTUA aldizkarirako ere erreportaia egin ziguten.
#KZgunea-k Debagoieneko bailaran azken 20 urte hauetan izan duen bilakaera azalduz.
#IKT #TIC
goiena.eus/prentsa/

Zertan lan egiten dudan jakin nahi?
Oñatiko Irratiko lagunek elkarrizketa egin zidaten eta hemen daukazue entzungai.
#IKT #TIC
ivoox.com/onatiko-kzgu...
xn--oati-gqa.eus/eu/berbia/ir...
about.me/AitorMadrid
www.linkedin.com/in/aitormadr...

Ausgezeichneter Frontbericht über dringende und wichtige Themen im Bereich #IKT.

Mitnehmen:

- MEHR #DigitaleSouveränität
- MEHR Handlungsfreiheit
- MEHR MUTIGES POLITISCHES HANDELN
- MEHR Aufklärung in der Bevölkerung über Risiken
- WENIGER Erpressbarkeit von US BigTech
- WENIGER LAISSER-FAIRE

image

🎸【Amazon.co.jp限定】I.K.T (初回生産限定盤A) - 生田絵梨花 (メガジャケ付)

▼Amazon
商品ページはこちら！
▼メルカリ
商品ページはこちら！
▼DMM
商品ページはこちら！
▼Amazon Music Unlimited
商品ページはこちら！

#IKT #PR #フォロバ100

image

🎸【Amazon.co.jp限定】I.K.T (初回生産限定盤A) - 生田絵梨花 (メガジャケ付)

▼Amazon
商品ページはこちら！
▼メルカリ
商品ページはこちら！
▼DMM
商品ページはこちら！
▼Amazon Music Unlimited
商品ページはこちら！

#IKT #PR #フォロバ100

image

🎸【Amazon.co.jp限定】I.K.T (初回生産限定盤A) - 生田絵梨花 (メガジャケ付)

▼Amazon
商品ページはこちら！
▼メルカリ
商品ページはこちら！
▼DMM
商品ページはこちら！
▼Amazon Music Unlimited
商品ページはこちら！

#IKT #PR #フォロバ100

Grafik mit der Überschrift „Call for Papers“ zur 24. ZEW Conference on the Economics of Information and Communication Technologies. Die Konferenz findet am 25.–26. Juni 2026 in Mannheim statt. Modernes, abstraktes Design in Grün- und Blautönen mit geometrischen Elementen und dem ZEW-Logo.

🚨 #CallforPapers: 24. #ZEW-Konferenz zum Thema Economics of Information & Communication Technologies, Keynotes von Emilio Calvano (LUISS University) & Chiara Farronato (Harvard Business School), 25./26.6 | Mannheim
🗓️Einreichungsfrist: 25.2.
🔗 zew.de/ict-conferen...
Wir freuen uns auf Beiträge! #IKT

Grafik mit der Überschrift „Call for Papers“ zur 24. ZEW Conference on the Economics of Information and Communication Technologies. Die Konferenz findet am 25.–26. Juni 2026 in Mannheim statt. Modernes, abstraktes Design in Grün- und Blautönen mit geometrischen Elementen und dem ZEW-Logo.

🚨 #CallforPapers: 24. ZEW-Konferenz zum Thema Economics of Information & Communication Technologies, Keynotes von Emilio Calvano (LUISS University) & Chiara Farronato (Harvard Business School), 25./26.6 | Mannheim
🗓️Einreichungsfrist: 25.2.
🔗 zew.de/ict-conferen...
Wir freuen uns auf Beiträge! #IKT

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants Inhibikase Therapeutics (NASDAQ: IKT) priced an underwritten public offering to raise approximately $100.0 million in gross proceeds. The company is offering 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares. Common shares are priced at $1.45 each; pre-funded warrants at $1.449 each (reflecting a $0.001 exercise price). Underwriters have a 30-day option to buy up to 10,344,827 additional shares. The offering is expected to close on November 24, 2025, subject to customary closing conditions.Jefferies, BofA Securities and Cantor are joint book-running managers; other managers include LifeSci Capital, Oppenheimer, H.C. Wainwright and Ladenburg Thalmann.

#IKT Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/IKT/inhibikase-ther...

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Inhibikase Therapeutics (NASDAQ: IKT) on Nov 20, 2025 announced a proposed underwritten public offering of common stock and, for some investors, pre-funded warrants exercisable for common stock. The company also intends to grant underwriters a 30‑day option to purchase up to an additional 15% of the shares at the public offering price, less underwriting discounts and commissions.The offering is being made from a shelf registration on Form S-3 (No. 333-288213) declared effective June 27, 2025, is subject to market and other conditions, and may not be completed. Jefferies, BofA Securities and Cantor are joint book‑running managers; LifeSci Capital and Oppenheimer are co‑lead managers; H.C. Wainwright and Ladenburg Thalmann are co‑managers. A preliminary prospectus supplement will be filed with the SEC.

#IKT Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/IKT/inhibikase-ther...

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension Inhibikase Therapeutics (Nasdaq: IKT) plans to initiate a global pivotal Phase 3 study of IKT-001 in pulmonary arterial hypertension in Q1 2026. The adaptive two-part IMPROVE-PAH trial expects Part A as a double-blind, placebo-controlled study in 140 patients with primary endpoint PVR at Week 24, and Part B in 346 patients with primary endpoint 6MWD at Week 24. The design includes a 12-week dose-titration, uninterrupted enrollment between parts, and potential sample-size re-estimation; the study may run in about 180 global sites. IKT-001 is described as a prodrug of imatinib with expected improved gastrointestinal tolerability and a stated potential to accelerate an NDA timeline by ~3 years.

#IKT Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

www.stocktitan.net/news/IKT/inhibikase-ther...

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today

#IKT Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

www.stocktitan.net/news/IKT/inhibikase-ther...

Boden gutmachen: Wenn Start-ups aus der Großstadt an Tools für Landwirte tüfteln Am Freitag präsentieren sich junge Berliner Firmen, überwiegend aus den Branchen IKT, Medien und Kreativwirtschaft, auf dem „Berlin Creative Tech Summit 2025“. Mit dabei das smarte Team von CinSOIL

Berlin Creative Tech Summit 2025: A Preview (paywall). #CinSOIL #NENNA.AI #IHKBerlin #KI #AI #startup #deeptech #IKT www.tagesspiegel.de/berlin/berli...

Instituto Kodigos de Tecnologia abre 8 vagas de emprego em Manaus O Instituto Kodigos de Tecnologia (IKT) anuncia a abertura de oito vagas de emprego para profissionais de tecnologia: cinco para Desenvolvedor Fullstack e três para Desenvolvedor Pleno O post Instituto Kodigos de Tecnologia abre 8 vagas de emprego em Manaus apareceu primeiro em Band Amazonas.

Ein bayerisch-tirolerischer Quantencomputer soll ÖBB-Züge pünktlicher machen Ein Forschungsprojekt soll den täglichen Frust von Pendlern und Reisenden dämpfen. Normale Rechner leisten dafür offenbar zu wenig

2-3 mobile Technikteams mehr hätten wahrscheinlich einen größeren Effekt auf die Pünktlichkeit als quantencomputergestützte Problemanalysen. Aber was weiß ich schon! 🤷‍♀️ #ÖBB #OeBB #DB #Bahn #IKT

Inhibikase Posts Wider Loss in Q2 | The Motley Fool

#IKT #17df2473-5c5a-44d8-8d70-c01d36753c0e #data-news

Origin | Interest | Match

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity Inhibikase Therapeutics (Nasdaq: IKT) reported Q2 2025 financial results and provided updates on its PAH drug development program. The company is preparing to launch IMPROVE-PAH, a Phase 2b clinical study for IKT-001, their re-engineered prodrug of imatinib mesylate, in the second half of 2025.The study will involve 150 PAH participants randomized to receive either 300mg IKT-001, 500mg IKT-001, or placebo. Previous studies showed imatinib's efficacy in PAH, with patients on 400mg achieving a 45-meter improvement in 6-minute walk distance. The company ended Q2 2025 with $87.7 million in cash and reported a net loss of $9.9 million ($0.11 per share).

#IKT Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

www.stocktitan.net/news/IKT/inhibikase-ther...

Genieße 50 Stunden Spielzeit und 85 % mehr Bass mit den kabellosen IKT Kopfhörern! Perfekter Sound für jeden Anlass. 🎶 #BluetoothKopfhörer #InEar #IKT

👩‍💻 2023an Euskal AEko IKTen sektorearen negozio-zifra 5.307 milioi €koa (📈%7,8) izan zen. Sektore hori EAEko ekonomiaren balio erantsiaren eta enpleguaren % 2,4 da

🔗https://f.mtr.cool/jnfespdikg

#IKT

Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development New leadership team drives Phase 2b trial preparation for PAH treatment IKT-001. Strong $93.2M cash position funds clinical advancement. Get full insights.

#IKT Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

www.stocktitan.net/news/IKT/inhibikase-ther...

Good Job or Flop?
ver.di fragt: Wie gut ist deine Arbeit wirklich?
Jetzt mitmachen bei der ver.di IKT-Befragung (6.5.–30.6.2025)

QR-Code scannen oder hier klicken:
gute-arbeit-ikt.verdi.de

#verdi #guteArbeit #IKT #GoodJobOrFlop #Mitmachen #Umfrage #ITJobs #Digitalarbeit #Betriebsrat

Purcell & Lefkowitz LLP Investigates Inhibikase Therapeutics for Shareholder Rights Purcell & Lefkowitz LLP is conducting an investigation into Inhibikase Therapeutics, focusing on potential breaches of fiduciary duties by the company's directors.

Purcell & Lefkowitz LLP Investigates Inhibikase Therapeutics for Shareholder Rights #United_States #New_York #Purcell_&_Lefkowitz #Inhibikase #IKT

Öva, träna, traggla, drilla och repetera!
Detta är en av grunderna inom allt lärande.

Testa mina fria skolappar. app.digitalaverktyg.se
#ikt #digitalaverktyg #specialpedagogik #utbildning #skola

Intryck från SETT Sthlm: Frustrationen är stor - att bara "slänga ut skärmarna" löser inte skolans problem. Relationer med eleverna är viktigast! Spännande AI-verktyg, men medvetenhet om risker och klok användning är centralt. #utbildning #digitalaverktyg #ikt #ai

Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth Fresh FDA clearance and $110M funding boost position Inhibikase for Phase 2b PAH trial advancement. New executive team to lead clinical development. See full financial details.

#IKT Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

www.stocktitan.net/news/IKT/inhibikase-ther...

Grafik: Mindmap mit verschiedenen digitalen Medien. Text: Digitale Medien in der Lehramtsausbildung. (Zylka & Müller: 2011)

Digitale Medienkompetenz ist für Lehrkräfte essenziell, doch wie wird sie im Studium gefördert? Die Integration digitaler Medien in die Lehramtsausbildung. Jetzt lesen!
#DigitaleBildung #Lehramt #Medienkompetenz #IKT #Bildungsforschung
⬇️
buff.ly/n1tVBEp

The Female Student Travel Award #FSTA25 is back! Are you a student passionate about science and technology? This is your chance to attend leading events connecting female researchers in computer science and engineering—we cover the expenses!
Find out more: https://buff.ly/4hMlcVG
#resilience #ikt